Business Context and Reporting Period
This Form 8-K was filed by Vanda Pharmaceuticals Inc. on March 23, 2018, reporting a material event regarding its intellectual property rights. The company is a Delaware corporation focused on the development and commercialization of HETLIOZ (tasimelton) for Non-24-Hour Sleep-Wake Disorder.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal and regulatory event rather than financial performance.
Material Changes
On March 23, 2018, Vanda received a Paragraph IV certification notice from Teva Pharmaceuticals USA, Inc. regarding an Abbreviated New Drug Application (ANDA) for a generic version of the 20mg HETLIOZ capsule. Teva alleges that six specific patents covering methods of using HETLIOZ are invalid, unenforceable, and/or will not be infringed. The latest of these patents expires in 2034.
Outlook, Risks, and Management Commentary
- Management Response: Vanda is reviewing the notice and intends to vigorously enforce its intellectual property rights.
- Legal Timeline: Vanda has 45 days from the notice date to initiate a patent infringement lawsuit.
- Regulatory Impact: Filing a lawsuit would automatically preclude the FDA from approving Teva's ANDA for 30 months or until a district court decision is entered, whichever is earlier.
- Patent Portfolio: The composition and use of HETLIOZ are currently protected by seven issued patents listed in the FDA's Orange Book.
Investor Verification Checklist
- Verify the specific patent numbers cited in the notice (9,060,995; 9,539,234; 9,549,913; 9,730,910; 9,855,241; RE46,604) and their remaining expiration dates.
- Monitor whether Vanda files a patent infringement lawsuit within the statutory 45-day window.
- Assess the potential impact of a generic entry on HETLIOZ sales projections if the patents are invalidated or not enforced successfully.
- Review the status of the other six patents in the Orange Book not explicitly challenged in this specific notice.